Alirocumab
Brand name: Praluent Pen
Rank #109 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$165.6M
Total Cost
203,805
Total Claims
$165.6M
Total Cost
6,684
Prescribers
$813
Cost per Claim
15,940
Beneficiaries
310,818
30-Day Fills
$25K
Avg Cost/Provider
30
Avg Claims/Provider
Share of Medicare Part D Spending
0.06%
of total Medicare Part D spending
$165.6M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $165.6M total
🔎 Data Overview
Average cost of $10,392 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Alirocumab
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Scott Merryman | Family Practice | Columbus, OH | 1,051 | $876K |
| 2 | Janice Mcalister | Nurse Practitioner | Atlanta, GA | 611 | $749K |
| 3 | James Trippi | Cardiology | Indianapolis, IN | 529 | $686K |
| 4 | James O'keefe | Cardiology | Kansas City, MO | 398 | $498K |
| 5 | Diane Osborn | Nurse Practitioner | Portland, OR | 390 | $470K |
| 6 | Patrick Moriarty | Internal Medicine | Kansas City, KS | 662 | $455K |
| 7 | Daniel Soffer | Internal Medicine | Media, PA | 401 | $452K |
| 8 | John Isaac | Cardiology | Houston, TX | 569 | $429K |
| 9 | Leandro Slipczuk Bustamante | Cardiology | Philadelphia, PA | 385 | $421K |
| 10 | Denise Janosik | Cardiology | Saint Louis, MO | 420 | $383K |
| 11 | Raveen Arora | Cardiology | Anaheim, CA | 432 | $377K |
| 12 | Gayley Webb | Nurse Practitioner | Philadelphia, PA | 377 | $374K |
| 13 | Weston Whittington | Cardiology | Fort Collins, CO | 267 | $323K |
| 14 | Anna Milstein | Cardiology | Los Angeles, CA | 564 | $311K |
| 15 | Joette Hughes | Nurse Practitioner | Lancaster, PA | 387 | $273K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 106 | Duloxetine Hcl (Duloxetine Hcl) | $167.7M | 5,106,690 |
| 107 | Sucroferric Oxyhydroxide (Velphoro) | $166.8M | 54,837 |
| 108 | Lifitegrast (Xiidra) | $166.6M | 149,269 |
| 109 | Alirocumab (Praluent Pen) | $165.6M | 203,805 |
| 110 | Pantoprazole Sodium (Pantoprazole Sodium) | $165.1M | 10,061,854 |
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology